COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0HH3W
|
|||
Drug Name |
VBY-825
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Investigative | [1] | |
Therapeutic Class |
Antiviral Agents
|
|||
Structure |
Download2D MOL
|
|||
Formula |
C23H29F4N3O5S
|
|||
Canonical SMILES |
CCC(C(=O)C(=O)NC1CC1)NC(=O)C(CS(=O)(=O)CC2CC2)NC(C3=CC=C(C=C3)F)C(F)(F)F
|
|||
InChI |
1S/C23H29F4N3O5S/c1-2-17(19(31)22(33)28-16-9-10-16)30-21(32)18(12-36(34,35)11-13-3-4-13)29-20(23(25,26)27)14-5-7-15(24)8-6-14/h5-8,13,16-18,20,29H,2-4,9-12H2,1H3,(H,28,33)(H,30,32)/t17-,18-,20-/m0/s1
|
|||
InChIKey |
PPUXXDKQNAHHON-BJLQDIEVSA-N
|
|||
CAS Number |
CAS 1310340-58-9
|
|||
PubChem Compound ID |
References | Top | |||
---|---|---|---|---|
1 | A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals. April 17, 2020. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.